U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced plans for a nationwide advertising campaign encouraging Americans to adopt health wearables, such as heart rate and continuous glucose monitors. The initiative is part of the department’s broader “Making America Healthy Again” (MAHA) agenda.
Speaking before the House Energy and Commerce Committee’s Health Subcommittee, Kennedy emphasized the importance of personal health data. “My vision is that every American is wearing a wearable within four years,” he said. “It’s a way for people to take control of their health—seeing real-time impacts of food on glucose levels and heart rate.”
The announcement boosted shares of glucose-monitoring device makers. Dexcom (NASDAQ:DXCM) surged 10%, while Abbott gained 3.6% in afternoon trading.
Kennedy, a longtime advocate for preventive health and a critic of overreliance on pharmaceuticals, pointed to the cost-effectiveness of wearables compared to popular weight-loss drugs. “Ozempic costs $1,300 a month. If you can achieve similar results with an $80 wearable, that’s a better deal for Americans,” he noted. While he has criticized drugs like Novo Nordisk’s Ozempic, Kennedy supports their use for patients with morbid obesity or diabetes, when combined with exercise.
The campaign, which he described as one of the largest in HHS history, aims to shift the focus from reactive to proactive health management. Kennedy also hinted at exploring ways to subsidize wearables to make them more accessible.
J.P. Morgan analyst Robbie Marcus cautioned against assuming immediate changes in Medicare or insurance coverage for proactive monitoring, saying it’s too early to predict policy shifts.
The wearable tech market stands to benefit from this government push, as health monitoring tools become more mainstream in personal wellness strategies.


Drones Spotted Near Zelenskiy’s Flight Path in Ireland Trigger Security Alert
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
U.S. Soybean Shipments to China Gain Momentum as Trade Tensions Ease
Trump Warns Drug-Trafficking Nations as Colombia’s Petro Issues Strong Rebuttal
U.S. Repatriation Flight Carrying 266 Venezuelan Migrants Lands in Caracas
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Federal Judge Blocks Trump Administration’s Medicaid Funding Restrictions Targeting Planned Parenthood
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
U.S.–Russia Peace Talks Stall as Kremlin Rejects Key Proposals
Trump Pardons Former Honduran President Juan Orlando Hernández in Controversial Move 



